Novartis appoints Elizabeth Barrett as CEO of Oncology
11 January 2018 -

Novartis (VTX: NOVN) has appointed Elizabeth Barrett as CEO of Novartis Oncology and a member of the Executive Committee of Novartis, effective 1 February, the company announced on Thursday.

Barrett will be based in Basel and will succeed Bruno Strigini, who has decided to retire from the company for personal reasons.

She will be joining Novartis from her current role as global president of Oncology at Pfizer Inc (NYSE: PFE), where she led the oncology business through a significant period of growth in less than three years.

Before joining Pfizer in 2009, Barrett held numerous leadership position in the pharmaceutical industry, as well as in the consumer sector, having worked at Cephalon Inc and Johnson & Johnson (NYSE: JNJ).

Novartis also revealed that Robert Kowalski, head of Global Regulatory Affairs, will assume ad interim leadership of the Drug Development Organisation, effective 1 February. Dr Kowalski has held the role of head of Global Regulatory Affairs at the company since February 2016. Novartis will announce the definitive head of Global Drug Development in due course.